25省(区、市)抗肿瘤药物中标价格分析
x

请在关注微信后,向客服人员索取文件

篇名: 25省(区、市)抗肿瘤药物中标价格分析
TITLE:
摘要: 目的:研究我国25省(区、市)药品集中采购的抗肿瘤药物中标价格差异,为进一步完善我国药品集中采购工作提供参考。方法:搜集我国25省(区、市)药品集中采购中抗肿瘤药物通用名、中标厂家、中标价格等数据,利用均数、中位数、标准差、四分位数间距(QR)和变异系数(CV)等指标对各省(区、市)中标抗肿瘤药物整体情况、化学类与中成药抗肿瘤药物价格差异、各省(区、市)同一品种药品中标价格差异、各厂家同一品种药品在不同省(区、市)的中标价格差异、同一品种进口药与国产药中标价格差异、同厂家生产的同规格同剂型的紫杉醇注射液在各省(区、市)的中标价格差异等进行对比分析。结果:25省(区、市)中标抗肿瘤药物共652种,平均中标价格为(669.92±2 513.17)元,中位价格为104.35元,QR=254.28,CV=3.75;化学类抗肿瘤药物的平均中标价格是中成药抗肿瘤药物的6.57倍;有431种(66.10%)药品在不同省(区、市)最高中标价格与最低中标价格差异倍数分布在1倍之内;各省(区、市)有436种(66.87%)药品中标价格的CV<0.2;14种药品的中标厂家超过10家,其中有5种药品的CV>0.5;63种进口药品的CV=2.10,国产药品的CV=1.90。同厂家同规格同剂型的紫杉醇注射液在不同省(区、市)的高中标价格者是低价者的1.5~4.5倍。结论:各省(区、市)同种药品中标价格较为集中,各厂家同种药品中标价格较为离散,同种进口药品中标价格普遍高于国产药品。
ABSTRACT: OBJECTIVE: To study the differences for bidding price of anti-tumor drugs in centralized drug procurement, and to provide reference for further perfecting centralized drug procurement of province(region,city) in China. METHODS: The data of centralized drug procurement were collected from 25 provinces(region,city) in terms of general name of anti-tumor drugs, bidding manufacturers, bidding price, etc. Using mean, median, standard deviation, quartile range (QR) and coefficient of variation (CV) as index, the following aspects were compared and analyzed, including the situation of bidding anti-tumor drugs in each province(region,city), the difference of chemicals price with Chinese patent medicines price, the difference of bidding price of same category in each province(region,city), the difference of bidding price of same category in each manufacturers, the difference of bidding price of same category between imported drugs and domestic drugs, the difference of bidding price for Paclitaxel injection with same specification and dosage form from same manufacturers in each province(region,city). RESULTS: In 25 provinces(region,city), number of bidding anti-tumor drugs was 652, the average bidding price was (669.92±2 513.17) yuan, the median price was 104.35 yuan, QR=254.28, CV=3.75. The average bidding price of chemical anti-tumor drugs was 6.57 times as much as that of Chinese patent medicines. For 431 (66.10%) kinds of drugs, the distribution of difference between the highest bidding price and the lowest bidding price was within 1 times; CV of bidding price for 436 kinds (66.87%) was less than 0.2; pharmaceutical manufacturers of 14 drugs were more than 10, among which CV of 5 drugs was more than 0.5. CV of 63  imported drugs was equal to 2.10, and that of domestic drugs was equal to 1.90. The difference of bidding price for Paclitaxel injection from same manufacturer in different province(region,city) ranged 1.5-4.5 times from the higher to lower. CONCLUSIONS: The bidding price of same category is concentrated in each province(region,city). The bidding price of same category from different manufacturers is dispersed. The imported drugs are more expensive than domestic drugs.
期刊: 2016年第27卷第31期
作者: 袁姣,周健丘,陈宇,刘杨正,毛宗福
AUTHORS: YUAN Jiao,ZHOU Jianqiu,CHEN Yu,LIU Yangzheng,MAO Zongfu
关键字: 抗肿瘤药物;药品集中采购;中标价格;均数;变异系数;化学药;中成药;进口药;国产药
KEYWORDS: Anti-tumor drugs; Centralized drug procurement; Bidding price; Mean; Coefficient of variation; Chemicals; Chinese patent medicine; Imported drug; Domestic drug
阅读数: 273 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!